| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (November 9, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, to... |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSE... |
| 25 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (August 6, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, toda... |
| 29 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This AGREEMENT AND PLAN OF MERGER, dated as of June 28, 2026 (this “Agreement”), is entered into by and among Theravance Biopharma, Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “... |
| 14 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Vancouver, British Columbia (May 14, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today a... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (May 7, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today r... |
| 01 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS AGREEMENT is made and effective as of April 1, 2026 (the “Effective Date”), regardless of the last date of signature hereto. |
| 02 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (March 2, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI |
| 30 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On Tuesday, December 30, 2025, Zymeworks Inc. (the “Company”), held its 2025 annual meeting of stockholders (the “Annual Meeting”) at 9:00 a.m. Pacific Time, virtually via live audio webcast. As of the close of business on November 3, 20... |
| 18 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders |
| 17 Nov 2025 |
8-K: Other Events
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (November 6, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-... |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Vancouver, British Columbia (September 2, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult... |
| 11 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Stock Purchase Agreement (this “Agreement”) is dated as of August 10, 2025, by and between Zymeworks Inc., a Delaware corporation (the “Company”), and Gregory A. Ciongoli (the “Purchaser”). |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (August 7, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to... |
Loading...